|
HSS Maternal Mortality Working group
|
Committee, Work group, Advisory group, or Task Force
|
HRSA, CDC
|
OD/DPCPSI/ORWH, NICHD
|
Serves as an ORWH representative on the HHS Office of Women's Health Working Group
|
|
Human Papillomavirus (HPV) Working Group for the Advisory Committee on Immunization Practices (ACIP)
|
Committee, Work group, Advisory group, or Task Force
|
CDC
|
NCI
|
The Human Papillomavirus (HPV) Working Group for the Advisory Committee on Immunization Practices (ACIP) Work Groups (WGs) serves in a key scientific role in support of vaccine policy development by the ACIP. ACIP WGs conduct extensive background reviews of relevant research data to develop options for recommendations for use of vaccines in the civilian population of the United States. WGs are convened solely to gather scientific information related to vaccines and the diseases they prevent, to analyze relevant issues and data, and to draft policies or options for review, deliberation, and vote by the ACIP.
|
|
Human skin sensitization data set
|
Research Initiative
|
FDA
|
NIEHS
|
NICEATM and collaborators collected data for over 2,300 human predictive patch tests from more than 1,700 publications.
|
|
I-Corps @ NIH
|
Training Initiative
|
CDC
|
NCI, NCATS, NCCIH, NHGRI, NHLBI, NIA, NIAAA, NIAID, NICHD, NIDA, NIDCD, NIDCR, NIEHS, NIMH, NINDS
|
The I-Corps™ at the National Institutes of Health (NIH) program is focused on educating researchers and technologists on how to translate technologies from the lab into the marketplace. The program is designed to provide three-member project teams with access to instruction and mentoring in order to accelerate the translation of technologies currently being developed with NIH and the Centers for Disease Control and Prevention (CDC) Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) funding. It is anticipated that outcomes for the I-Corps™ teams participating in this program will include significantly refined commercialization plans and well-informed pivots in their overall commercialization strategies.
|
|
IAA with FDA - Using big data to compare SARS-CoV-2 infection and therapeutic efficacy between human lung on a chip and animal model testing
|
Resource Development
|
FDA
|
NIAID
|
This collaboration will allow the development of in vitro organ on a chip technology for modeling of SARS-CoV-2 infection, identification of biomarkers and transcriptomic and tissue expression imaging by MIBI/CODEX. The data collected from the organ on a chip systems will then be compared to ongoing analysis of human clinical samples and parallel testing in animal models of COVID.
|
|
ICCVAM Ecotoxicology Workgroup (EcoWG)
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NIEHS
|
ICCVAM workgroup that provides expertise in identifying and evaluating in vitro and in silico methods to identify ecological and environmental hazards.
|
|
ICCVAM In Vitro to In Vivo Extrapolation Workgroup (IVIVE-WG)
|
Committee, Work group, Advisory group, or Task Force
|
ATSDR, FDA
|
NIEHS, NLM
|
ICCVAM workgroup established to catalog and evaluate currently available IVIVE approaches, to determine their suitability for specific research or regulatory purposes, and to assess whether additional tools or models are needed.
|
|
ICCVAM Metrics Workgroup (MWG)
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NIEHS, OD
|
ICCVAM workgroup established to develop objectives and determine how agencies can best address the recommendations in the 2019 GAO report, "Animal Use in Research"
|
|
ICCVAM Nanomaterials Workgroup (NanoWG)
|
Committee, Work group, Advisory group, or Task Force
|
FDA, CDC
|
NIEHS
|
ICCVAM workgroup established to evaluate the suitability of alternative methods to assess potential toxicity of nanomaterials.
|
|
ICCVAM Public Forum
|
Meeting/ Workshop
|
FDA
|
NIEHS, NCATS
|
ICCVAM holds annual public forums to promote national and international partnerships between governmental and nongovernmental groups, including academia, industry, advocacy groups, and other key stakeholders. The 2020 Public Forum was held on May 21.
|